Final answer:
Option A. Dupilumab is the correct answer, as it is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, and is used in the treatment of moderate-to-severe asthma.
Step-by-step explanation:
The monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, which are involved in asthma pathophysiology, is Dupilumab. Therefore, the correct answer is A) Dupilumab. This medication is designed to target and block the IL-4 receptor alpha subunit, thus inhibiting the action of IL-4 and IL-13, which are key drivers of Type 2 inflammation that can contribute to several diseases, including asthma.
Dupilumab is administered by subcutaneous injection and is used in the treatment of moderate-to-severe asthma in patients who are inadequately controlled on their current asthma medications. Dupilumab is the correct answer, as it is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, and is used in the treatment of moderate-to-severe asthma.